Cite
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.
MLA
Tan, Darrell H. S., et al. “Inflammatory Biomarker Levels over 48 Weeks with Dual vs Triple Lopinavir/Ritonavir-Based Therapy: Substudy of a Randomized Trial.” PLoS ONE, vol. 14, no. 9, Sept. 2019, pp. 1–13. EBSCOhost, https://doi.org/10.1371/journal.pone.0221653.
APA
Tan, D. H. S., Rolon, M. J., Figueroa, M. I., Sued, O., Gun, A., Kaul, R., Raboud, J. M., Szadkowski, L., Hull, M. W., Walmsley, S. L., Cahn, P., & null, null. (2019). Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial. PLoS ONE, 14(9), 1–13. https://doi.org/10.1371/journal.pone.0221653
Chicago
Tan, Darrell H. S., Maria Jose Rolon, Maria Ines Figueroa, Omar Sued, Ana Gun, Rupert Kaul, Janet M. Raboud, et al. 2019. “Inflammatory Biomarker Levels over 48 Weeks with Dual vs Triple Lopinavir/Ritonavir-Based Therapy: Substudy of a Randomized Trial.” PLoS ONE 14 (9): 1–13. doi:10.1371/journal.pone.0221653.